ÂÜÀòÂÒÂ×

Andrew Kuzmission is an experienced professional in regulatory affairs and analytical development within the pharmaceutical industry. Currently serving as Vice President of Regulatory Affairs CMC at Vertex Pharmaceuticals, Andrew has progressed through roles including Executive Director and Senior Director, overseeing regulatory CMC activities throughout clinical development, marketing authorization approval, and post-approval changes. Andrew's prior experience includes leadership positions at Johnson & Johnson and McNeil Consumer Healthcare, where oversight of analytical teams and development initiatives contributed to successful NDA and MAA filings. Andrew holds a Ph.D. in Analytical Chemistry from The Ohio State University and a BS in Chemistry from Bucknell University. Additionally, Andrew has contributed to academia as an Adjunct Professor at Temple University.